Patient cohort
A total of 186 charts of patients treated at the Hôpitaux Universitaires de Genève (HUG) with rituximab met the following inclusion criteria of newly diagnosed histologically proven aggressive B-cell lymphoma and treated with at least two consecutive doses of fractionated rituximab 24 hours apart during the first cycle of treatment. Patients were excluded if they had non-B-cell lymphoma histology, administration of a single dose of rituximab, required chronic dialysis, were under 18-year old and in the absence of written informed consent. The Ethics Committee of Geneva (CCER 2020-01659) approved the study. Written informed consent was obtained in accordance with the declaration of Helsinki from alive patients (hospital general consent for clinical data use), and a waiver was applied for deceased patients when obtaining consent was not possible.